CBP501 Evidence: Trial Results and Peer-Reviewed Publications
Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:
The clinical evidence base for CBP501 comprises 8 peer-reviewed publications across 6 journals, 0 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Pancreatic Neoplasms, Neoplasms, Mesothelioma, Malignant, and Lung Neoplasms. Most recent publication: A multicenter, randomized phase 2 study to establish combinations of CBP501, cisplatin and nivolumab for ≥3rd-line treatment of patients with advanced pancreatic adenocarcinoma., Eur J Cancer, 2024.
Top peer-reviewed publications
Curated set of pivotal-trial result papers and recent publications in high-tier journals.
- Phase I studies of CBP501, a G2 checkpoint abrogator, as monotherapy and in combination with cisplatin in patients with advanced solid tumors.Shapiro GI, Tibes R, Gordon MS, et al. · Clin Cancer Res · 2011
- A multicenter, randomized phase 2 study to establish combinations of CBP501, cisplatin and nivolumab for ≥3rd-line treatment of patients with advanced pancreatic adenocarcinoma.Enzler T, Nguyen A, Misleh J, et al. · Eur J Cancer · 2024
- Sensitization of cancer cells to DNA damage-induced cell death by specific cell cycle G2 checkpoint abrogation.Suganuma M, Kawabe T, Hori H, et al. · Cancer Res · 2000
- Cell cycle phenotype-based optimization of G2-abrogating peptides yields CBP501 with a unique mechanism of action at the G2 checkpoint.Sha SK, Sato T, Kobayashi H, et al. · Mol Cancer Ther · 2007
- CBP501-calmodulin binding contributes to sensitizing tumor cells to cisplatin and bleomycin.Mine N, Yamamoto S, Saito N, et al. · Mol Cancer Ther · 2012
- Activation of Nrf2 pathways correlates with resistance of NSCLC cell lines to CBP501 in vitro.Mine N, Yamamoto S, Kufe DW, et al. · Mol Cancer Ther · 2015
- Screening of a library of T7 phage-displayed peptides identifies alphaC helix in 14-3-3 protein as a CBP501-binding site.Matsumoto Y, Shindo Y, Takakusagi Y, et al. · Bioorg Med Chem · 2012
- Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma.Krug LM, Wozniak AJ, Kindler HL, et al. · Lung Cancer · 2015
Publications by year
2000–2024: 8 publications.
2000
1
2007
1
2011
1
2012
2
2015
2
2024
1
Publications by indication
Pancreatic Neoplasms (3)
- A multicenter, randomized phase 2 study to establish combinations of CBP501, cisplatin and nivolumab for ≥3rd-line treatment of patients with advanced pancreatic adenocarcinoma.
- Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma.
- CBP501-calmodulin binding contributes to sensitizing tumor cells to cisplatin and bleomycin.
Neoplasms (2)
- Screening of a library of T7 phage-displayed peptides identifies alphaC helix in 14-3-3 protein as a CBP501-binding site.
- Phase I studies of CBP501, a G2 checkpoint abrogator, as monotherapy and in combination with cisplatin in patients with advanced solid tumors.
Mesothelioma, Malignant (1)
- Sensitization of cancer cells to DNA damage-induced cell death by specific cell cycle G2 checkpoint abrogation.
Lung Neoplasms (1)
- Cell cycle phenotype-based optimization of G2-abrogating peptides yields CBP501 with a unique mechanism of action at the G2 checkpoint.
Publications by journal
- Mol Cancer Ther3 papers
- Clin Cancer Res1 paper
- Eur J Cancer1 paper
- Cancer Res1 paper
- Bioorg Med Chem1 paper
- Lung Cancer1 paper
All CBP501 publications (8)
2024 (1 paper)
- A multicenter, randomized phase 2 study to establish combinations of CBP501, cisplatin and nivolumab for ≥3rd-line treatment of patients with advanced pancreatic adenocarcinoma.Enzler T, Nguyen A, Misleh J, et al. · Eur J Cancer · 2024 · Derived
2015 (2 papers)
- Activation of Nrf2 pathways correlates with resistance of NSCLC cell lines to CBP501 in vitro.Mine N, Yamamoto S, Kufe DW, et al. · Mol Cancer Ther · 2015 · Background
- Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma.Krug LM, Wozniak AJ, Kindler HL, et al. · Lung Cancer · 2015 · Background
2012 (2 papers)
- CBP501-calmodulin binding contributes to sensitizing tumor cells to cisplatin and bleomycin.Mine N, Yamamoto S, Saito N, et al. · Mol Cancer Ther · 2012 · Background
- Screening of a library of T7 phage-displayed peptides identifies alphaC helix in 14-3-3 protein as a CBP501-binding site.Matsumoto Y, Shindo Y, Takakusagi Y, et al. · Bioorg Med Chem · 2012 · Background
2011 (1 paper)
- Phase I studies of CBP501, a G2 checkpoint abrogator, as monotherapy and in combination with cisplatin in patients with advanced solid tumors.Shapiro GI, Tibes R, Gordon MS, et al. · Clin Cancer Res · 2011 · Trial result
2007 (1 paper)
- Cell cycle phenotype-based optimization of G2-abrogating peptides yields CBP501 with a unique mechanism of action at the G2 checkpoint.Sha SK, Sato T, Kobayashi H, et al. · Mol Cancer Ther · 2007 · Background
2000 (1 paper)
- Sensitization of cancer cells to DNA damage-induced cell death by specific cell cycle G2 checkpoint abrogation.Suganuma M, Kawabe T, Hori H, et al. · Cancer Res · 2000 · Background
Sources and methodology
- Publications:
ctgov.study_references(PubMed PMIDs auto-attached by ClinicalTrials.gov to each trial), reference typesRESULT,DERIVED, andBACKGROUND. - Per-arm outcome values:
ctgov.outcome_measurementsjoined toctgov.design_outcomeswhereoutcome_type = 'PRIMARY', restricted to phasePHASE3andPHASE2/PHASE3. - Publication metadata (title, journal, year, authors): PubMed E-utilities
efetch.fcgi - Data freshness: Tue, 26 May 2026 18:14:10 GMT.
This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).